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Introduction
Despite dramatic advances over the past decade in understanding the molecular biology of cancer and innovations in drug development technology, translation of these findings into effective cancer treatments remains difficult. The application of modern technologies to study genomic alterations associated with cancer growth and progression has provided for targeted development of new treatment options for patients with specific molecular abnormalities (biomarkers). Particularly, non-small cell lung cancer (NSCLC) is a disease in which a number of molecular targets have been identified (1) (2) (3) . Great strides have been made in efficient and successful development of molecularly-targeted drugs [e.g., crizotinib, ceritinib, and alectinib for patients bearing anaplastic lymphoma kinase (ALK) fusions (4-7); and epidermal growth factor receptor [EGFR] mutations (3, 8, 9) ]. However, developing a potential therapeutic agent from the initial discovery stage through clinical testing and regulatory review still remains a complicated, expensive, and inefficient process. Even rationally developed targeted therapies fail late in development because relevant patient populations were not selected or preliminary data were inadequate (e.g., promising phase 2 results not recapitulated in phase 3) (10) . The consequences of this often slow and complicated process is either delay or failure to offer new active drugs to the many desperate patients with lung cancer (or other cancers). However, identifying and accruing biomarkerselected patients to clinical trials is also challenging. This is particularly true for squamous cell carcinoma (SCCA) of NSCLC. Since any putative oncogenic driver in SCCA is rare, screening patients for solitary biomarker-driven studies requires substantial time and tissue with a low chance of enrollment-in fact, serial screening for individual biomarkers to determine eligibility for other trials is not feasible for SCCA patients who have already progressed on standard therapy. Thus, new strategies are essential for matching patients to therapies from which they are most likely to benefit, requiring efficient clinical trial designs for evaluating these therapies, with rapid, multi-biomarker patient evaluation and accelerated drug development timelines (11) (12) (13) .
biomarkers present in their tumors. This design allows more efficient screening and facilitates the addition of new drugs and biomarkers into the protocol on a rolling basis.
Two categories of studies follow this design ( Fig. 1 and Table 1) : "Basket" studies examine the effect of specific therapeutic agent(s) on a defined molecular target regardless of the underlying tumor-type. This design facilitates a particular targeted therapeutic strategy (i.e., inhibition of an oncogenically mutated kinase) across multiple cancer types. Examples are the National Cancer Institute's (NCI's) Molecular Analysis for Therapy Choice (MATCH) (15) and the Molecular Profiling based Assignment of Cancer Therapeutics (MPACT) trials. The second type, "Umbrella" studies, evaluate multiple targeted therapeutic strategies in a single type of cancer. Examples are Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And molecular Analysis 2 (I-SPY TRIAL 2, I-SPY 2) (16), the FOCUS4 study in advanced colorectal cancer (17) , and the phase 2 adaptive randomization design Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) (18) and BATTLE-2 (14, 19) in NSCLC.
The Lung Master Protocol (Lung-MAP) is a recently initiated umbrella trial specifically for patients with advanced lung SCCA. It is built on the principles and approaches of the previously mentioned trials. Particularly, I-SPY 2 established infrastructure for conduct of a Master Protocol [including development of the Master Investigational New Drug application with the US Food and Drug Administration (FDA)] (16), and it has been successful in meeting its objectives of matching drugs with subtypes of breast cancer in which they are most likely to be effective, potentially leading to smaller phase 3 trials in the selected subpopulations (20, 21) . BATTLE and BATTLE-2 are direct precursors of Lung-MAP that have been successful in developing strategies to screen patients for and to define biomarkers for optimal patient selection for evaluation of drugs and drug combinations that have shown promise in treatment of NSCLC (18, 19) . Although based on concepts developed in I-SPY 2 and the BATTLE trials, Lung-MAP has a different overall strategy. It does not use adaptive randomization to evaluate drug/biomarker combinations and it goes beyond phase 2 development. It is designed to provide a path for FDA-approval of active agents identified in the initial phase 2 study. That is, a drug that is found to be effective in phase 2 will move directly into the phase 3 registration setting, incorporating the patients from phase 2. This will reduce time, resources and patient numbers needed to accomplish the ultimate goal of bringing novel agents to the clinic. Lung-MAP also addresses other unmet needs including applications of broad-based genomic screening in clinical trial settings, and shortened turnaround times to allow effective use of molecular testing in selection of therapy for patients who are progressing rapidly. This Master Protocol mechanism is expected to increase access to genomic screening for SCCA patients, improve definition of genomically defined biomarkers for clinical trial entry for these patients, and decrease time lines for drug-biomarker testing allowing for inclusion of the maximum numbers of otherwise eligible patients (13). The authors hope that this article will increase awareness of Lung-MAP in the research community, allow us to share our experience with other groups looking to launch similar projects, and motivate oncologists to offer Lung-MAP as a treatment option to their eligible patients.
The concept for Lung-MAP was developed jointly in 2012 by the NCI's Thoracic Malignancy Steering Committee (TMSC) (7) Here we describe the study design, initial selection of drugs and biomarkers, additional translational medicine studies that might be carried out under Lung-MAP, and a further discussion of the challenges and benefits of the Master Protocol design.
Study Design
The overarching goal for this trial is to establish an NCTN mechanism for genomically screening large, clinically well-defined cancer populations and assigning screened patients to substudies within a Master Protocol. These substudies are defined by genotypic alterations (biomarkers) in the tumor paired to drugs that target these alterations. Fig. 2 shows the general schema for Lung-MAP. For screening, patients must have adequate tumor tissue for evaluation from either archival formalin-fixed paraffin-embedded (FFPE) or fresh tumor biopsies; archival tissue must be a tumor block or a minimum of 12 FFPE slides 4-5 microns thick (20 slides preferred). Patients ≥ 18 years of age, with adequate tissue and pathologically proven advanced-stage lung SCCA (Stage IIIB or IV), without known EGFR mutations or ALK fusions, whose disease has progressed on exactly one first-line platinumbased therapy (or therapy plus radiation treatment) for metastatic lung cancer, and with Zubrod Performance Scores ≤2.0, who have had no prior malignancies except adequately treated basal and squamous cell skin cancers and cervical cancers in situ, treated Stage I/II cancers from which they are in complete remission, or other cancers from which they have been disease-free for at least five years, are evaluated using next generation DNA sequencing (NGS) along with additional agent-specific molecular assays for the presence of relevant biomarkers. A key factor in the efficiency of the Master Protocol design is rapid turnaround of screening results to establish substudy eligibility (within 10-14 days). Eligible patients are then assigned to substudies based on their biomarkers or to a "non-match" therapy substudy if the patient does not qualify for the biomarker-specific substudies. For enrollment to a substudy, patients must have measurable disease as measured by CT or MRI; if treated for brain metastases, they must have had sufficient time for recovery. They will not have not had within the past 28 days and are not planning to have other cancer therapy while on study; have no EGFR mutations or ALK translocations detected during screening; have recovered fully from drug treatment or surgery for their lung cancer; have adequate organ function and Zubrod Performance Scores ≤2.0, and meet other criteria specific to the substudy to which they are assigned. Within the substudies, patients are randomized to biomarker-driven targeted or standard-of-care (SOC) therapy. In some substudies, targeted therapy plus SOC is compared with SOC. Fig. 3 shows the overall schema with the five initial substudies (four targeted therapies and one non-match therapy), and Table 2 provides details of the initial substudies.
SCCA accounts for approximately 20-35% of lung cancer incidence annually (8, (22) (23) (24) (25) (26) . Based on this statistic and the widespread availability of the protocol throughout the NCTN, accrual of 500-1,000 patients per year is expected in 4-7 concurrent substudies. New substudies will enter the trial on a rolling basis as substudies close, or relevant drugbiomarker pairs with sufficient proof-of-concept become available. Each substudy functions autonomously, opens and closes independently, and is analyzed independently of the other substudies. The duration estimates for each substudy are based on historical data regarding the prevalence of the associated biomarker among lung SCCA patients. These estimates may be modified as needed based on the actual prevalence among patients accrued to the study using the Lung-MAP specific assays (See Table 3 ). The duration for each substudy is approximately inversely proportional to prevalence and the accrual is expected to range from 2-7 years through phase 3. Each substudy will require approximately 300-400 patients to complete phase 3.
Patients with tumors bearing more than one relevant biomarker are assigned to a substudy based on a pre-defined algorithm that helps facilitate even enrollment across all substudies. Initially the algorithm will be based on observations in previous studies of lung SCCA relevant to the drugs on study, e.g., the evaluation of 108 tumors by NGS carried out on the Foundation Medicine (FMI) FoundationOne platform (Fig. 3) . In this analysis, overlaps of 2.8%, 0.9%, and 2.0% were estimated for the FGFR biomarker with the CDK, PIK3CA, and c-MET biomarkers, respectively; overlaps of 1.9% and 2.8% were estimated for the CDK biomarker with the PIK3CA and c-MET biomarkers, respectively; and overlap of 1.9% was estimated for the PIK3CA and c-MET biomarkers. The algorithm will be modified as needed during the course of Lung-MAP to accommodate the actual prevalence of overlaps observed for the biomarkers on study. A non-match substudy will be open to accrual throughout the trial, ensuring that all enrolling patients receive treatment on protocol.
Each substudy specifies investigator-assessed progression-free survival (IA-PFS) and overall survival (OS) as the co-primary endpoints for the phase 3 primary objectives. The primary objectives for phase 3 are to determine if there is a statistically significant difference in OS and to determine if there is both a clinically meaningful and statistically significant difference in IA-PFS. The phase 2 interim analysis in each trial is a "go-no go" decision based on IA-PFS to either continue accruing patients or to close the study for lack of evidence of efficacy at a phase 2 sample size (8) . Along with the paired biomarker, drugs that satisfy the primary objectives have the potential for registration. The choice of PFS as a co-primary endpoint for phase 3 was made in collaboration with NCI and FDA, based on the well-known difficulties in obtaining unconfounded OS in trials in advanced lung cancer (27) . The bar for PFS is high. In phase 2, target HR is 0.5 (at least a two-fold increase over controls; based on 55 progression events, yielding 90% power, 10% type 1 error); the approximate threshold for continuing to phase 3 is the observation of at least a 41% improvement in median PFS (HR=0.71). In phase 3, the sample size for each substudy is based on a target of 50% improvement in median OS (HR=0.67), with 90% power and a 2.5% 1-sided type 1 error rate, requiring 256 deaths. The approximate threshold for clinically and statistically significant PFS is 75% improvement in median PFS (HR=0.57), based on 290 events, power 90%, and type 1 error rate=0.014. Drug companies may also choose more stringent criteria for phase 2.
Negative trials will be interpreted only as failure of the specific therapeutic agent, and other drugs inhibiting the same target will be considered for future arms as appropriate (e.g., drugs or drug combinations with different specificity for the target and/or different toxicity profiles).
Biomarkers and Drugs
Detailed genomic analysis has identified potential therapeutic targets in over 60% of lung SCCA patients; each of these targets exists in a relatively rare subset of patients (2) . Biomarkers for these targets of interest within Lung-MAP are defined by specific genomic alterations (mutations, amplifications, rearrangements) detected by NGS using the FMI FoundationOne platform (28), supplemented with immunohistochemistry assays (to detect over-expression of the actionable target) or other methodologies as appropriate, performed in a Clinical Laboratory Improvement Amendment (CLIA)-approved setting. It is anticipated that the NGS-defined biomarker will often be a suitable companion diagnostic for registration purposes. The rationale for an NGS-based screening approach stems from the identification in SCCA of multiple genetic alterations that are putative oncogenic "drivers," the comprehensive coverage of markers ensuring a high hit rate, and the short turnaround time for obtaining results (Fig. 4) .
Candidate drugs are evaluated by a multidisciplinary drug selection committee using specific criteria such as demonstrated biologic activity against the target associated with a proposed predictive biomarker(s), well-understood mechanism of activity against the target, evidence of clinical activity in cancer, particularly in squamous cell cancers (e.g., phase 1 responders), manageable toxicity, and practical dosage regimens that are acceptable to the patient and clinician. To date, the study team has focused on monotherapy, but understands, as described below, that more effective therapy may be achieved by targeting multiple components of signaling pathways simultaneously and will begin to explore combinations of targeted drugs. Drug and biomarker selection will be a continuous process during Lung-MAP to replace drugs or drug combinations that leave the study; to ensure that the nonmatch drug arm is always open to accrual; and to add substudies with new drugs or drug combinations/targets. Drug selection for Lung-MAP is a fluid process, intended to be responsive to research advances. The Drug Selection Committee meets frequently, up to monthly, as needed. As described above, when current drugs leave Lung-MAP, other drugs or drug combinations for their targets also may be considered. Candidate drugs will be sought from multiple sources including interested pharmaceutical companies, clinical investigators, and comprehensive literature surveys. Although the primary focus of Lung-MAP is on strategies with targeted drugs, the non-match substudy is also important. It both allows the exploration of new therapies with expected broad ranging activity across cancers, such as immunotherapy [represented by the current non-match substudy with the antiprogrammed death receptor ligand 1 (anti-PD-L1) drug MEDI4736], and provides a way to offer screen negative patients access to a promising agent in a clinical trial setting.
Finally, Lung-MAP will provide a rich resource of tissue, blood, and imaging associated with well-documented clinical outcomes from patients with refractory lung SCCA for additional translational medicine studies. Considering that SCCA is one of the most genetically complex of all tumor types, it is anticipated that many lung SCCA tumors will require combination therapies to simultaneously inhibit multiple oncogenic drivers and overcome innate resistance mechanisms, likely necessitating custom-tailored regimens for each patient based on their unique tumor genetic profiles. Tackling this complexity will require not only comprehensive marker assessment, but a constant reevaluation and optimization of treatment outcomes that can only be conducted in a systematic clinical trial setting. The typical approach of clinical trials evaluating single biomarker-single treatment pairs in isolation will not be transformative. Additionally, while the comprehensive analysis of genetic alterations provided by NGS technology, including DNA mutations, insertions, deletions, copy number abnormalities, and chromosomal aberrations, is by far the most promising screening approach currently available, analysis of protein disposition may prove equally informative in some instances, necessitating development of additional biomarker assays. Lastly, analysis of blood-borne biomarkers has seen a recent resurgence subsequent to the development of highly sensitive, highly accurate analytics. Many research groups are currently developing approaches to investigate cell-free tumor DNA in peripheral circulation or detailed multiplexed analysis of circulating tumor cells. In addition to obviating the need for arduous and expensive tumor biopsies, theoretical advantages to a blood-based biomarker approach include reduced sampling error from individual biopsies in heterogeneous tumors such as SCCA, and the ability to detect emergence of acquired resistance mechanisms/alternative drivers over the course of therapy. The serial blood draws collected from each patient enrolled inLung-MAP, added to the comprehensive tumor tissue analysis, will provide an invaluable resource for accelerated development of predictive blood-based biomarkers. The central collection of imaging data will allow for a better understanding of the radiomic signature of SCCA, understanding of the image based response and progression in these subsets and the potential to centrally verify IA-PFS.
Discussion-Challenges and Benefits
There are challenges to Lung-MAP, and to cancer drug development generally, that can be tackled as the study progresses, and the strategies for handling the challenges can be incorporated into designs to facilitate future trials. One example is that the Lung-MAP approach requires large and rapid accrual from many sites. This is addressed in part by the NCTN mechanism, which coordinates activities between different Cooperative Group research sites and their affiliates, allowing Lung-MAP to be offered as a clinical trial option at hundreds of institutions and treatment centers around the country, and potentially internationally. In order to accelerate access to as many sites as possible, Lung-MAP utilizes the NCI Central IRB (CIRB). By doing so, individual research institutions that allow the CIRB to replace institutional IRBs have fewer administrative steps to activating the trial, while maintaining the safety of study participants. Use of the CIRB is currently optional for NCTN sites; however, its use will become mandatory in 2015. While the general NCTN site qualification procedures are cost-effective and rigorous regarding requirements for study staff and facilities, they do not suffice for ensuring that adequate awareness, training, staff, and facilities are in place for individual studies across the NCTN. Additional qualification and planning activities through direct contact with sites, NCTN wide webinars, and regional investigator meetings are warranted.
Another challenge is that Lung-MAP requires commitment by pharmaceutical partners and the FDA to ensure that the trial provides a regulatory approval pathway. To support this, all partners-NCI, FDA, pharmaceutical companies, academic leaders, SWOG, Friends, and FNIH-have been involved in the design and development of the study as a whole, as well as of individual substudies. Further, it is difficult to conduct randomized trials in settings where patients have multiple options for obtaining treatment with targeted agents. In order to reduce confusion and help patients reach the best decisions for their care, a system has been put in place for Lung-MAP to provide guidance to physicians and patients on evaluation of screening results.
Finding the best drugs is another challenge. More than 100 candidate drugs were reviewed to identify the five in the first round of Lung-MAP. In many cases, exciting new drugs do not have the supporting clinical data needed for immediate selection for Lung-MAP. To address this, a pipeline could be established via phase 1/2a studies to identify candidates early in development and seamlessly develop needed data for the new candidate to become eligible for Lung-MAP. Another issue for access to drugs is company concerns regarding risks to primary development paths for their drugs. Although the costs to pharmaceutical companies for Lung-MAP are much less than for individual company-run studies, they are still significant. Particularly, the burden to smaller companies that may have exciting drugs but limited development resources should be considered in funding strategies.
Finally, the importance of integrating measures of patient reported outcomes (PROs) into clinical trials is increasingly recognized. Lung-MAP will incorporate PROs so that this added dimension is accounted for in judging the overall impact of new therapies.
In summary, Lung-MAP is a public-private collaboration where each partner is committed to rapidly identify new active drugs for SCCA NSCLC and to shorten the approval pathway (29) . Lung-MAP is a new model for high-quality drug development in less time, at less cost, and, most importantly to improve the lives of patients with lung cancer. The benefits of this approach are summarized in Text Box 1 (29) . The shared goal of accelerating the pace in which new drugs are developed is the driving force behind the Lung-MAP partnership.
Text Box 1
Benefits of Lung-MAP approach for drug development
• Grouping biomarker driven targeted drug studies under a single trial will reduce the screen failure rate, making the screening efficient and worthwhile for both patients and physicians
• Operational and protocol development efficiencies are provided by the Master Protocol framework. For example, consistency is provided by applying the Master Protocol-every drug for the disease would be tested in the identical manner
• A regulatory approval pathway is provided for drugs and companion diagnostic biomarkers
• Shared infrastructure for screening, database, enrollment, site management, etc. is less costly than in individual studies
• Improvement in overall efficiency of drug development is provided in a specific disease setting, bringing safe and more effective drugs to patients sooner than they might otherwise be available Umbrella and Basket Trials. The trials listed are currently on-going or soon to be activated trials with Umbrella or Basket designs with partial funding from US or United Kingdom governments. Details of these studies are presented in Lung-MAP Study Schema. Fresh tumor biopsy or archival FFPE tumor from eligible patients with Stage IIIB or IV lung SCCA whose disease has progressed on first-line therapy is evaluated using NGS (FoundationOne) and, in some cases molecular assays (e.g., IHCbased), carried out in a CLIA-certified laboratory for the presence of drug-specific biomarkers relevant to lung SCCA that may serve as targets for drugs currently under study in Lung-MAP. Results are returned within 10-14 days of tissue submission. Patients are then assigned to substudies based on their biomarkers or to a non-match therapy substudy; within the substudies the patients are randomized to biomarker-driven targeted or SOC therapy. Patients with more than one relevant biomarker are assigned to substudies based on an algorithm designed to best balance accrual among the substudies. Accrual and treatment in phase 2 continues within each substudy until a sufficient number of progression events has been observed to estimate whether or not a drug will likely be successful in the phase 3 component. Drugs meeting PFS criteria will continue on in phase 3 until a sufficient number of progression events has occurred to determine whether or not the targeted drug regimen shows statistically and clinically significant improvement in PFS over SOC. Patients will be followed for up to three years to determine effects on OS. Prevalence of Genomic Alterations in Lung SCCA. This chart shows the prevalence and pattern of mutations, amplifications and rearrangements seen in 108 consecutive FFPE lung SCCA tumor samples sequenced using the FMI FoundationOne platform to an average unique median depth (the number of times a given region has been sequenced by independent reads) of >500x. This plot highlights the diversity of alterations in lung SCCA and the importance of a comprehensive genomic assessment with respect to both the number of genes assessed and alteration types. • Anti-PD1 and anti-PD-L1 monoclonal antibodies are active in NSCLC, work is on-going to define selected populations that will derive most benefit from treatment with these agents (39, 40) Column 1 lists the four targeted therapies (TTs) and one non-match therapy (NMT) that comprise the initial set of drugs being evaluated in Lung-MAP. Column 2 shows the arms of the substudies. Three of the TTs are being evaluated as monotherapy against chemotherapy (docetaxel) (CT); the fourth is being evaluated in combination with erlotinib (E) against E. Table 3 Comparison of prevalence of gene alteration in the substudy eligibility criteria between Foundation Medicine (FMI) and TCGA This table compares prevalence of gene alterations in the substudy eligibility criteria between FMI and TCGA lung SCCA datasets (p-values from Fisher's exact test shown). The observed prevalences are similar between the two datasets, with the exception of FGFR1 amplifications, observed at a lower prevalence in the FMI dataset. TCGA data of SCCA (2) was retrieved using cBioPortal (41, 42) . This table compares prevalence of gene alterations in the substudy eligibility criteria between FMI and TCGA lung squamous cell carcinoma datasets (p-values from Fisher's exact test shown). The observed prevalences are similar between the two datasets, with the exception of FGFR1 amplifications, observed at a lower prevalence in the FMI dataset. Because FMI detects copy number alterations by fitting a statistical copy-number model to normalized coverage and allele frequencies, while the TCGA data used in this comparison was generated using the GISTIC algorithm (43) and application of a per-sample variable threshold, the absolute level at which amplifications are called could not be directly compared. Given that amplifications in the FMI approach are called at an estimated 6 copies or above and adjusted to 7 copies for triploid and 8 copies for tetraploid specimens, it is likely that the difference is explainable by the more stringent definition of amplification in the FMI approach.
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